Abstract
With advances in surgical techniques and chemotherapeutic agents, mortality rates from epithelial ovarian cancer (EOC) have slightly decreased over the last 30 years. However, EOC still ranks as the most deadly gynecologic cancer with an overall 5-year survival rate of 45%. Prognosis is especially disappointing for women with platinum-resistant disease, where 80% of patients will fail to respond to available therapies. Emerging treatment strategies have subsequently focused on targets which are integral to tumor growth and metastasis. In this review, we will focus on those innovative agents currently under investigation in clinical trials.
| Original language | English |
|---|---|
| Pages (from-to) | 25-38 |
| Number of pages | 14 |
| Journal | Cancer Management and Research |
| Volume | 3 |
| Issue number | 1 |
| State | Published - 2011 |
| Externally published | Yes |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Angiogenesis
- Growth factors
- Immunotherapy
- Ovarian cancer
- Platinum-resistant
- Targeted therapy
Fingerprint
Dive into the research topics of 'Targeted treatment of recurrent platinum-resistant ovarian cancer: Current and emerging therapies'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver